DALLAS — In patients with moderate to very severe chronic obstructive pulmonary disease who had a history of exacerbations, were on double or triple therapy and had eosinophilic inflammation, add-on benralizumab did not reduce the rate of exacerbations more than placebo, according to the GALATHEA and TERRANOVA studies presented at the American Thoracic Society International Conference.
The randomized, phase 3, double-blind, placebo-controlled, parallel-group GALATHEA and TERRANOVA trials enrolled patients aged 40 to 85 years with moderate to severe COPD who were still experiencing frequent exacerbations despite receiving guideline-directed medical therapy in a 2:1 fashion based on whether their eosinophil counts were greater or less than 220 cells/µL.
This educational activity is supported by an educational grant from GlaxoSmithKline.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.